CD137 (4-1BB) /NF-κB Reporter - HEK293 Recombinant Cell Line

Catalog #

79289

$11,095 *

Size: 2 vials

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

Recombinant HEK293 cell line expressing a full length human CD137 (4-1BB) (NM_001561). The NF-ĸB luciferase reporter construct is stably integrated into the genome. The firefly luciferase gene is controlled by 4 copies of NF-κB response element located upstream of the TATA promoter. Following activation by human CD137 ligand, NF-ĸB transcription factors bind to the DNA response elements to induce transcription of the luciferase gene.

Interested in screening and profiling inhibitors, blocking antibodies, or activators of CD137 without the need to purchase and license the cell line? Check out our Cell Signaling Pathway Screening.

This product has been cited 1 time.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

●

Synonyms

CD137, 4-1BB, nfkb, nfkb, nf-kb

●

Product Data Gallery

Dose response of CD137/ NF-κB-reporter HEK293 cells

Expression of CD137 (4-1BB) protein validated by flow cytometry

Product Info

Storage and Usage

Citations1

Host Cell Line

HEK293

Materials Required But Not Supplied

Format

Each vial contains 2 x 10^6 cells in 1 ml of 10% DMSO in FBS.

UniProt #

Q07011

Mycoplasma Testing

This cell line has been screened using the MycoAlert™ Mycoplasma Detection Kit (Lonza, #LT07-118) to confirm the absence of Mycoplasma contamination.

Background

Human CD137 (4-1BB; TNFRS9) is an inducible co-stimulatory molecule that activates T cells. CD137:CD137L-mediated signaling has been shown to be important for proliferation, effector functions and survivals of T cells. CD137 is also expressed in NK and NKT cells. Accumulating evidence shows a role for CD137:CD137L signaling in inflammation, suggesting that inhibition of this pathway may provide a therapeutic avenue to treat autoimmune and inflammatory diseases. Similarly, antibodies targeting CD137 activation in immune cells have demonstrated potent anti-tumor properties in cancer patients.

References

1. McNamara II JO et.al. (2008) Multivalent 4-1BB binding aptamers co-stimulate CD8+ T cells and inhibit tumor growth in mice. J. Clin. Invest. 118: 376-386
2. Ma BY et.al. (2005) The expression and regulatory role of OX40 and 4-1BB heterodimers in activated human T cells. Blood. 106: 2002-2010.

Storage/Stability

Store in liquid nitrogen immediately upon receipt.

Growth Media

For best results, it is highly recommended to use these validated and optimized media from BPS Bioscience. Other preparations or formulations of media may result in suboptimal performance.

Thaw Medium 1 (BPS Bioscience, #60187): MEM medium supplemented with 10% FBS, 1% non-essential amino acids, 1 mM Na pyruvate, 1% Penicillin/Streptomycin

Growth Medium 1G (BPS Bioscience, #79544): MEM medium supplemented with 10% FBS, 1% non-essential amino acids, 1 mM Na pyruvate, 1% Penicillin/Streptomycin plus 400 µg/ml G418 (Geneticin) and 50 µg/ml Hygromycin B

Shipping Temperature

-80°C

Notes

License Disclosure
Visit bpsbioscience.com/license for the label license and other key information about this product.

Troubleshooting Guide
Visit bpsbioscience.com/cell-line-faq for detailed troubleshooting instructions. For all further questions, please email [email protected].

Scientific Category

Immunotherapy

Regulatory Status

Research Use Only